Security key
19240Q201
Cogent Biosciences, Inc. - Common Stock (COGT)
CUSIP: 19240Q201
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 159,224,831
- Total 13F value
- $2,286,403,568
- Share change
- +23,217,570
- Put/Call ratio
- 43%
- SEC-reported price per share
- $14.36
- Number of holders
- 192
- Value change
- +$377,675,482
- Number of buys
- 124
- Number of sells
- 70
- Shares outstanding
- 170,962,250
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
192
Top holders
10
COGT full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Cogent Biosciences, Inc. SEC filings
Cogent Biosciences, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 19240Q201
Recent filing periods:
Ownership snapshot
Top reported holders of COGT - Cogent Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
30 Sep 2025
13F
13D/G
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
TCG Crossover GP I, LLC
4.8%
Venrock Healthcare Capital Partne...
4.2%
Point72 Asset Management, L.P.
4%
Paradigm Biocapital Advisors LP
2.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$122,623,401
17,078,468 shares
|
— | 30 Jun 2025 |
| TCG Crossover GP I, LLC |
13D/G
|
4.8%
|
$97,621,606
6,798,162 shares
|
$0 | 30 Sep 2025 |
| Venrock Healthcare Capital Partners II, L.P. |
13D/G
|
4.2%
|
$44,463,093
4,755,411 shares
|
-$15,815,581 | 30 Jun 2025 |
| Point72 Asset Management, L.P. |
13D/G
13F
Company
|
4%
|
$82,625,042
5,753,833 shares
|
-$60,775,814 | 30 Sep 2025 |
| Paradigm Biocapital Advisors LP |
13F
13D/G
Company
|
2.3%
from 13D/G
|
$74,330,584
10,352,449 shares
|
— | 30 Jun 2025 |
| BlackRock, Inc. |
13F
Company
|
5%
|
$61,938,850
8,626,581 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
192
Shares
159,224,831
Rows available
192
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
175
Q3 2025 holders
192
Holder diff
17
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend